Navigation Links
Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin(TM) in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.

In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy, the reduction in total nasal symptom score (TNSS). However, the TNSS data for placebo-treated patients was far lower than would be expected for the moderate to moderately severe patient population called for in the protocol. Low pollen counts in many of the regions during the time PreHistin was being tested may have resulted in low mean placebo symptom scores for the overall study population.

The trials showed that PreHistin was well tolerated and thus contributed positively to the safety record of PreHistin's active ingredient, cyanocobalamin.

A comparison of pre- and post-treatment blood levels of cobalamin demonstrated for the first time in a large study population that delivery of cyanocobalamin via sublingual lozenges resulted in significant increases in cobalamin blood levels.

Cobalis' Chief Scientific Officer Ernest Armstrong commented: "Showing a meaningful reduction in allergy symptoms when the symptoms never increased throughout the pollen season to the desired moderate to moderately severe level is next to impossible. It's like trying to prove that a pump can pump water out of a swimming pool when there is almost no water in the pool to begin with. Other pharmaceu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cobalis Expects to Report Phase III Top-Line Results in May
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/5/2015)... 2015  Adeptus Health Inc. (NYSE: ADPT ) ... of the previously announced offering of 2,100,000 shares of ... are to be sold by the Company, and 750,329 ... Sterling Partners (the "Selling Stockholder"), at a price to ... Company and the Selling Stockholder have granted the underwriters ...
(Date:5/5/2015)... N.J. , May 5, 2015  CorMedix Inc. ... and commercializing therapeutic products for the treatment of infectious ... financial results on May 7.  Randy Milby , ... conference call on Friday, May 8 at 9:00 a.m. ... the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 (outside ...
(Date:5/5/2015)... 5, 2015  CipherHealth, a leading provider of innovations ... care, sent representatives to the Nepalese American Nursing Association ... their nurses to Nepal to ... last month. In addition to helping fund the travel ... utilized for much-needed medical supplies for the mission.  ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015 2Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2
... Volcano Corporation (NASDAQ: VOLC ) today ... year, the Massachusetts Superior Court rejected claims by ... Medical, that Volcano Corporation and its wholly-owned subsidiary, ... for use in the development of Volcano,s Optical ...
... Tigris Pharmaceuticals, Inc., today announced enrollment of its first ... AFP-464 (aminoflavone prodrug) with or without Faslodex® (fulvestrant) in ... be used to pre-screen patients for a biomarker called ... predict sensitivity to AFP-464. It is ...
Cached Medicine Technology:Statement From Volcano Corporation on Latest St. Jude Lawsuit 2Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 2Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 3
(Date:5/5/2015)... PA (PRWEB) May 05, 2015 The 2015 ... raised $110,000 to benefit their global research, outreach and patient ... silent auction, and awards ceremony that attracted hundreds of supporters. ... of the discovery of the hepatitis B virus (HBV) by ... Blumberg received the Nobel Prize in Medicine for his discovery ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 The newly minted ... the experiences of Dr. Brad Reedy from his 20 ... Regan was asked why she chose to publish a parenting book ... a parent (and publisher) is the idea that it is a ... and our children are on the trek sometimes together and sometimes ...
(Date:5/5/2015)... Nutritional science and medical research has enabled ... health conditions and illnesses linked to carrying excess weight. ... eating methods to rid the body of dangerous toxins, ... fast and processed foods. Patients find the company’s ... report feeling better and losing excess fat within days. ...
(Date:5/5/2015)... This year, PolyU researchers garnered two ... Awards, three Gold Medals and four Silver Medals at ... follows: , (1) Grand Prize and Gold Medal with ... Design and Fitting, Principal Investigator: Dr Allan Chee-kooi CHAN, ... relies very much on the “mannequin” for many tasks ...
(Date:5/5/2015)... The brains of people with type 1 ... slower information processing, according to research led by the ... . , The findings indicate that clinicians should ... cognitive difficulties. If progressive, these changes could influence their ... the National Institutes of Health (NIH), is ...
Breaking Medicine News(10 mins):Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 3Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 4
... Additional beneficial effects on cardiometabolic risk factors beyond those ... drug rimonabant may not be due to the drug ... Drug and Therapeutics Bulletin (DTB). ,Advertisements ... Sanofi-Aventis) claim that an estimated 50% of the effects ...
... Cryo-Save Group NV together with the University of Cologne ... collect adult mesenchymal stem cells ("MSCs") from the ... allows the collection and cryopreservation of very high quantities ... ,Mesenchymal stem cells (MSCs) are of great therapeutic ...
... current rehab spell will bring a stop to her suicidal ... ,As the Mean Girls star checked into the Promises ... arrested for DUI, her supposed friends got ready to reveal ... America's Star magazine that Lohan attempted to take her own ...
... to enter rehab in order to get rid of his addiction ... was recently snapped in a sleazy romp with two hookers, admitted ... ,"Im a bad boy. I go out and get drunk, ... with the wrong women. Ive been sowing my oats for years, ...
... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
... double current funding levels for the President's Emergency Plan ... years after the program's original mandate expires next year, ... $15 billion over five years for HIV/AIDS and tuberculosis ... the Global Fund To Fight AIDS, Tuberculosis and Malaria. ...
Cached Medicine News:Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Significant Scientific Breakthrough in Stem Cell Banking 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: